利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.021 秒)

    N-(PYRIDIN-4-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS
    1.
    发明公开
    N-(PYRIDIN-4-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS 审中-公开
    N-（吡啶-4-基）-2-苯基丁酰胺和去氧肾上腺素

    公开(公告)号：EP1912945A1

    公开(公告)日：2008-04-23

    申请号：EP06788817.2

    申请日：2006-07-28

    申请人： Merck & Co., Inc.

    发明人： MEISSNER, Robert, S. ,  PERKINS, James, J. ,  KIM, Yuntae ,  HANNEY, Barbara ,  MCVEAN, Carol, A.

    IPC分类号： C07D211/72 ,  C07D211/78 ,  A61K31/44

    CPC分类号： C07D213/61 ,  A61K31/44 ,  C07D213/64 ,  C07D213/65 ,  Y02A50/401

    摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    2-HYDROXY-2-PHENYL/THIOPHENYL PROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS
    6.
    发明公开
    2-HYDROXY-2-PHENYL/THIOPHENYL PROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS 审中-公开
    2-羟基-2-苯基/ THIOPHENYLPROPIONAMIDE ALS雄激素受体调节

    公开(公告)号：EP2083624A2

    公开(公告)日：2009-08-05

    申请号：EP07839564.7

    申请日：2007-10-15

    申请人： Merck & Co., Inc.

    发明人： KIM, Yuntae ,  MEISSNER, Robert S. ,  MITCHELL, Helen J. ,  PERKINS, James J. ,  ROSSI, Michael A. ,  WANG, Jiabing

    IPC分类号： A01N43/54 ,  A61K31/497 ,  A61K31/517

    CPC分类号： C07D213/40 ,  C07D409/12

    摘要： Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid- induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HFV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
    7.
    发明公开
    CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS 审中-公开
    羰苯并咪唑衍生物AS调节剂雌雄同体受体

    公开(公告)号：EP1581217A1

    公开(公告)日：2005-10-05

    申请号：EP03777969.1

    申请日：2003-10-28

    申请人： Merck & Co., Inc.

    发明人： KIM, Yuntae ,  SPENCER, Keith, L. ,  HANNEY, Barbara ,  DUGGAN, Mark, E.

    IPC分类号： A61K31/427 ,  C07D417/04

    CPC分类号： C07D417/04 ,  C07D401/04 ,  C07D403/04 ,  C07D417/14

    摘要： Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, arthritic condition and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.